LETTER TO EDITOR

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia

Angélique Chauvineau-Grenier1 · Paul Bastard2,3,4 · Jean-Laurent Casanova2,3,4,5 · Benjamin Rossi6

Received: 16 January 2022 / Accepted: 24 May 2022 / Published online: 8 June 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

To the Editor:

IL-6 receptor blocker tocilizumab is one of the approved treatments of hypoxemic COVID-19 pneumonia. It is recommended by World Health Organization since July 2021 for treatment of patients with severe or critical COVID-19 infection. Nevertheless, contradictory studies about its efficacy underlined the difficulty to best define the target populations that would most benefit from this treatment [1, 2].

Recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (INFs) in at least 15% of patients with critical COVID-19 pneumonia. Moreover, these auto-Abs were found in almost 20% of deceased patients across all ages [3], being risk of death greater and age dependant [4] and indicating the importance of type I IFN immunity in host defense against SARS-CoV-2 infection. We aimed to assess the clinical impact of tocilizumab on mortality in patients with or without auto-Abs to type I INFs in France, in the Seine-Saint-Denis department.

A cohort of 246 patients admitted for critical COVID-19 pneumonia was constituted in Robert Ballanger Hospital, Aulnay sous Bois, France, during the first wave of the pandemic. In this study, approved by a research ethics committee and registered on clinicaltrials.gov (NCT04366206), we assessed factors associated with clinical outcomes [2]. Critical COVID-19 pneumonia was defined by a pulse oxygen saturation (SpO2) ≤ 96% despite oxygen support ≥ 6 L/min with oxygen mask, for more than 6 h [3]. Less than half (106/246) of these patients were treated by tocilizumab, with a mean time between first symptoms and treatment of 9.5 ± 4.6 days. We previously found that a single 400-mg dose was globally associated with improved survival without mechanical ventilation in patients with critical COVID-19 in our cohort [2].

In the same cohort of 246 patients, 139 patients were retrospectively selected because of an available serum sample that was collected during the acute phase of disease and tested for the presence of auto-Abs neutralizing type I INFs [5]. A total of 7.9% (11 of 139) had circulating auto-Abs that neutralized 100 pg/mL IFN-α2 and/or IFN-ω (in plasma diluted 1/10) [5] (Fig. 1).

No differences were seen between patients with or without auto-Abs for comorbidities and biological characteristics at hospital admission. Although differences were not significant with the patients without neutralizing auto-Abs, most of patients with neutralizing auto-Abs were men (82%) and over the age of 65 years (82%) [5].

The presence of auto-Abs to type I INFs was associated with an increased risk of mortality, as 6 of 11 (55%) patients with auto-Abs died versus 23 of 128 (18%) of patients without auto-Abs (p = 0.01). We previously reported that 6 of 29 (21%) patients who died of COVID-19 pneumonia in our entire cohort had circulating auto-Abs capable of neutralizing 100 pg/mL type I INFs [5]. Deceased patients with auto-Abs did not present overt clinical differences with deceased patients without auto-Abs [5].

Six of the 11 patients (55%) with auto-Abs and 74 of the 128 patients (58%) without auto-Abs received tocilizumab (p = 1). Median time of administration after first symptoms did not differ between the two groups (8.5 [interquartile
range—IQR—5.25] days versus 9 [IQR, 6] days, $p = 0.7$) (Fig. 1).

Only 1 of 6 (17%) of deceased patients with neutralizing auto-Ab's received tocilizumab versus 12 of 23 (52%) of deceased patients without auto-Ab's, a difference that was not statistically significant ($p = 0.18$).

Interestingly, in patients with neutralizing auto-Ab's, only 1 of 6 (17%) patients who received tocilizumab died versus 5 of 5 (100%) patients who did not receive tocilizumab ($p = 0.01$). In contrast, in patients without neutralizing auto-Ab's, 12 of 74 (16%) of patients who received tocilizumab died versus 11 of 54 (20%) patients who did not receive tocilizumab ($p = 0.64$) (Table 1).

In patients with neutralizing auto-Ab's who were not mechanically ventilated and whose oxygen support became $< 6$ L during hospitalization, there was no difference in the length of critical period (with oxygen support $\geq 6$ L) between patients who received tocilizumab and patients who did not (Table 1).

In a surprising way, in patients without neutralizing auto-Ab's and who were not intubated, length of critical period was significantly shorter in patients who did not received tocilizumab but increased in patients who received tocilizumab, without a significant effect on mortality or the need of invasive mechanical ventilation (Table 1). These results might suggest that tocilizumab would increase length of critical period in patients without neutralizing auto-Ab's.

To note, very few patients were mechanically ventilated in our cohort that, as a reminder, was constituted during the first wave of the pandemic, with a limited number of places in intensive care unit. This may constitute a limitation to the interpretation of our results.

Overall, tocilizumab apparently showed somewhat better efficacy in reducing mortality in patients with than without neutralizing auto-Ab's to type I IFNs in our study without evident beneficial effect on length of critical period.

It is important to highlight that the low number of patients with auto-Ab's treated with tocilizumab is a significant limitation of this study and it will be necessary to confirm these results in larger cohorts. Meanwhile, the presence of auto-Ab's to type I IFNs might be considered when selecting which patients should receive tocilizumab when suffering from hypoxemic COVID-19 pneumonia. It would also be interesting to compare the impact of other immunosuppressants and corticosteroids on mortality in patients with or without auto-Ab's to type I IFNs.

---

**Fig. 1 Flow chart**

Patients admitted for critical COVID-19 pneumonia:
SpO2 $\leq 96\%$ with O2 support $\geq 6$ L/min with oxygen mask, for $> 6$ hours

Available serum sample collected during the acute phase of disease
$n = 139$

Detection of auto-Ab's neutralizing type I IFNs

| Detectable auto-Ab's | No detectable auto-Ab's |
|----------------------|-------------------------|
| $n = 11$             | $n = 128$               |
| Tocilizumab $n = 6$  | Tocilizumab $n = 74$    |
| Median time between first symptoms and administration: $8.5$ (IQR, $5.25$) days | Median time between first symptoms and administration: $9$ (IQR, $6$) days |

| No Tocilizumab | Tocilizumab |
|----------------|-------------|
| $n = 5$        | $n = 54$    |

---

$\copyright$ Springer
Table 1  Effect of tocilizumab in patients with neutralizing auto-Abs to type I IFNs

|                                      | Patients with neutralizing auto-Abs (n=11) | Patients without neutralizing auto-Abs (n=128) |
|--------------------------------------|--------------------------------------------|-----------------------------------------------|
|                                      | Tocilizumab | No tocilizumab | p     | Tocilizumab | No tocilizumab | p     |
| Poor outcome (invasive mechanical ventilation and/or death) | 1 (17%) | 5 (100%) | 0.01 | 18 (24%) | 20 (37%) | 0.17 |
| Invasive mechanical ventilation      | 0 (0%) | 1 (20%) | 0.45 | 10 (14%) | 10 (19%) | 0.47 |
| Death                                | 1 (17%) | 5 (100%) | 0.01 | 12 (16%) | 11 (20%) | 0.64 |
| Delay between first symptoms and first poor outcome | 14 | 16 (13) | NA | 13 (4.75) | 10.5 (7.75) | 0.28 |
| Median (IQR), days                   | 10 (7)   | 12.5 (6.5) | 0.69 | 6 (6.75)   | 3 (5.75)   | 0.03 |

Data are presented as a number (percentage) unless otherwise noted. Given the small samples size, a Fisher test was used to analyze the effect of dichotomous variables and a Mann–Whitney test for continuous variables. Significant values are noted in italics.

NA not assessable

Acknowledgements  We thank the patients and their families for placing their trust in us. We warmly thank the members of the Medical Biology Department of Robert Ballanger Hospital and the members of both branches of the Laboratory of Human Genetics of Infectious Diseases.

Author Contribution  Authors have participated in the conception and design, lab experiments, collection, analysis, and interpretation of the data, drafting the article, revising it critically for important intellectual content, and approval of the final version. ACG: conception and design, experiments in Robert Ballanger Hospital, analysis and interpretation of the data, drafting the article, revising it critically for important intellectual content, approval of the final version. PB: performed the experiments in Imagine Institute, analysis and interpretation of the data, drafting the article, revising it critically for important intellectual content, approval of the final version; JLC: revising it critically for important intellectual content, and approval of the final version.

Funding  The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; the Rockefeller University; the St. Giles Foundation; the National Institutes of Health (NIH) (R01Al088364); the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866); a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University; the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956); the Yale High Performance Computing Center (S10OD018521); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPBB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (EQU2019I03007798); the FRM and ANR GENCVID project (ANR-20-COV1-0003), ANRS Nord-Sud (ANRS-COVID), ANRS GENVIR (ANR-20-CEV9-003), and ANR AABIFNCOV (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics); the Square Foundation; Grandir — Fonds de solidarité pour l’enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; Institut National de la Santé et de la Recherche Médicale (INSERM); and the University of Paris. PB was supported by the French Foundation for Medical Research (FRM, EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller).

Data Availability  Clinical data files are stored at Robert Ballanger Hospital. It may be shared if needed.

Declarations

Ethics Approval  This study was approved by a research ethics committee and was registered on clinicaltrials.gov (NCT04366206).

Consent to Participate  Informed consent was obtained from the patients included in this study.

Consent for Publication  The authors affirm that patients included in this study provided informed consent for publication.

Competing Interests  JLC reports 2 patents pending, application number 63/055,155 filed July 22, 2020 and application number 63/141,669 filed January 26, 2021 pending.

References

1. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–16. https://doi.org/10.1056/NEJMoa2028700.
2. Rossi B, Nguyen LS, Zimmermann P, et al. Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case-control cohort study. Pharmaceuticals. 2020;13(10):317. https://doi.org/10.3390/ph13100317.
3. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.
Sci Immunol. 2021;6(62):eabl4340. https://doi.org/10.1126/sciimmunol.eabl4340.

4. Manry J, Bastard P, Gervais A et al. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies; preprint; In Review, 2022. https://doi.org/10.21203/rs.3.rs-1225906/v1.

5. Chauvineau-Grenier A, Bastard P, Servajean A, et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J Clin Immunol. 2022. https://doi.org/10.1007/s10875-021-01203-3.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.